Latest Strategy News

Baumart Holdings has recorded a nearly $1 million impairment on its mining equipment due to halted diamond mining operations and no clear plans for asset redeployment.

Avada Group Limited has updated its FY25 financial results, reducing its loss after tax by $2.04 million due to tax benefit adjustments and reclassification of borrowings, while confirming no impact on operating revenue or cash flow.

FirstWave Cloud Technology has locked in a $2.5 million loan facility to accelerate its AI growth strategy and repay existing debt, complementing a recent $2.85 million equity raise.

Judo Bank has successfully priced a $150 million Tier 2 subordinated notes issuance with a significantly tighter margin, reflecting its strengthened credit profile and strong investor demand.

Energy World Corporation’s final audited results for FY25 reveal a major loan-to-equity reclassification and a reshuffle of director fee liabilities, reshaping the company’s balance sheet.

ParagonCare has released its audited FY25 financial results, confirming steady profit while revealing a significant reclassification of debt and ongoing challenges with a major retail pharmacy receivable.

Altech Batteries has partnered with AMPower to immediately market and distribute sodium nickel chloride batteries across Europe, Australia, and the USA, fast-tracking revenue ahead of its large-scale CERENERGY project in Germany.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

The Star Entertainment Group has finalized a crucial covenant waiver with its syndicated lenders, easing financial pressures ahead of its FY2025 audited report. This development clarifies ongoing negotiations and sets the stage for the company’s next financial chapter.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.